Trade

with

Sarepta Therapeutics Inc
(NASDAQ: SRPT)
AdChoices
23.04
+0.75
+3.36%
After Hours :
23.59
+0.55
+2.39%

Open

22.46

Previous Close

22.29

Volume (Avg)

1.11M (1.29M)

Day's Range

22.05-23.60

52Wk Range

12.12-44.29

Market Cap.

942.88M

Dividend Rate ( Yield )

-

Beta

0.61

Shares Outstanding

40.92M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 14.22M

    • Net Income

    • -111.98M

    • Market Cap.

    • 942.88M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -730.66

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.61

    • Forward P/E

    • -6.75

    • Price/Sales

    • 55.56

    • Price/Book Value

    • 3.14

    • Price/Cash flow

    • -7.96

      • EBITDA

      • -89.01M

      • Return on Capital %

      • -43.38

      • Return on Equity %

      • -58.13

      • Return on Assets %

      • -43.38

      • Book Value/Share

      • 7.33

      • Shares Outstanding

      • 40.92M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 38.00

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -3.53

        • Cashflow Estimate

        • -2.69

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -12.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -7.73

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -730.66

            • 39.38

            • Net Profit Margin

            • -730.66

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -274.00

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.01

              • 0.76

              • Current Ratio

              • 10.36

              • 2.92

              • Quick Ratio

              • 9.68

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.12

              • 2.21

              • Book Value/Share

              • 7.33

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -7.43

                • 243.90

                • P/E Ratio 5-Year High

                • -18.37

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.86

                • 124.82

                • Price/Sales Ratio

                • 54.35

                • 9.29

                • Price/Book Value

                • 3.07

                • 8.39

                • Price/Cash Flow Ratio

                • -7.96

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -58.13

                    (-134.10)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -43.38

                    (-52.60)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -57.64

                    (-121.20)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.06

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -90.28M
                  Operating Margin
                  -634.95
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -7.96
                  Ownership

                  Institutional Ownership

                  64.64%

                  Top 10 Institutions

                  42.12%

                  Mutual Fund Ownership

                  36.82%

                  Float

                  99.74%

                  5% / Insider Ownership

                  28.08%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Columbia Acorn Fund

                  •  

                    2,552,000

                  • 0.00

                  • 6.24

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,096,532

                  • 0.00

                  • 2.68

                  • Lord Abbett Fundamental Equity

                  •  

                    857,849

                  • -37.84

                  • 2.10

                  • Lord Abbett Developing Growth Fund

                  •  

                    792,356

                  • 98.78

                  • 1.94

                  • SPDR® S&P Biotech ETF

                  •  

                    671,371

                  • -9.83

                  • 1.73

                  • Vanguard Small Cap Index

                  •  

                    640,220

                  • 0.35

                  • 1.56

                  • iShares Russell 2000 (AU)

                  •  

                    616,252

                  • -1.80

                  • 1.59

                  • Vanguard Total Stock Mkt Idx

                  •  

                    594,196

                  • 0.00

                  • 1.45

                  • iShares Nasdaq Biotechnology

                  •  

                    531,973

                  • -0.24

                  • 1.37

                  • Buffalo Small Cap Fund

                  •  

                    476,500

                  • 24.19

                  • 1.17

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Lord, Abbett & Co LLC

                  •  

                    3,074,622

                  • -6.33%

                  • 7.54

                  • Columbia Wanger Asset Management LLC

                  •  

                    2,633,000

                  • 0.00%

                  • 6.45

                  • Perceptive Advisors LLC

                  •  

                    2,558,478

                  • -11.13%

                  • 6.27

                  • Vanguard Group, Inc.

                  •  

                    2,229,951

                  • +5.99%

                  • 5.47

                  • BlackRock Fund Advisors

                  •  

                    1,390,644

                  • -1.35%

                  • 3.41

                  • D. E. Shaw & Co LP

                  •  

                    1,318,812

                  • +104.90%

                  • 3.23

                  • Fidelity Management and Research Company

                  •  

                    1,257,433

                  • +16.44%

                  • 3.08

                  • State Street Corp

                  •  

                    1,075,444

                  • -15.45%

                  • 2.64

                  • Gilder Gagnon Howe & CO LLC

                  •  

                    845,302

                  • +0.21%

                  • 2.07

                  • PointState Capital LP

                  •  

                    800,000

                  • +33.33%

                  • 1.96

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Sarepta Therapeutics Inc was incorporated in the State of Oregon on July 22, 1980. The Company discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The Company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases.

                  Key People

                  Mr. Christopher Garabedian

                  CEO/Director/President

                  William A. Goolsbee

                  Chairman of the Board/Director

                  Mr. Sandesh Mahatme

                  CFO/Chief Accounting Officer/Senior VP

                  Dr. Gil Price, M.D.

                  Director

                  Dr. Hans Wigzell

                  Director

                  Incorporated

                  1980

                  Employees

                  146

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: